Stockholm, April 4, 2022: Swedish molecular diagnostics company Elypta today announced the launch of its second clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). This study, LEVANTIS-0093A (LEV93A), aims to detect any-type cancer in adults at high risk of developing cancer due to significant smoking history.
Elypta will analyze blood samples prospectively collected within the Yorkshire Lung Screening Trial Biomarker sub-study and corresponding participant data prospectively collected within the Yorkshire Lung Screening Trial and the Yorkshire Kidney Screening Trial, all of which are sponsored by the University of Leeds and funded by Yorkshire Cancer Research, in collaboration with the University of Manchester, the University of Leeds, and the Leeds Teaching Hospitals NHS Trust.
Dr. Bethany Shinkins, Associate Professor of Health Economics in the University of Leeds School of Medicine, said: “The University of Leeds team is really excited to be collaborating with Elypta to support the evaluation of a novel biomarker that could help to detect cancer at an earlier stage, minimising the need for invasive and toxic treatments and increasing chances of survival. We would like to thank everyone who participates in the study.”
LEV93A, sponsored by Elypta, builds upon proof-of-concept data shared at the American Society of Clinical Oncology (ASCO) conference in June 2021 which indicated that GAGomes could detect one third of all stage I cancers across 14 types, including lung and kidney cancer. Elypta’s liquid biopsy exceed the performance of other proposed approaches that use biomarkers based on circulating tumor DNA, which have been shown to perform particularly poorly in kidney cancer despite the high prevalence of this lethal disease among high-risk adults.
LEV93A is the second study in MCED launched by Elypta, following the already initiated LEVANTIS-0087A study (NCT05235009),where the aim is to detect any-type cancer in adults who show no symptoms or have any recent history of cancer.
LEVANTIS-0093A(LEV93A) is a prospective cohort observational clinical study to validate the plasma free GAGome MCED test in adults at high risk of developing cancer(“high-risk adults”), specifically in 55–80-year-old adults with significant smoking history. LEV93A will use plasma biospecimens and corresponding patient data prospectively collected within the Yorkshire Lung Screening Trial (YLST)Biomarker sub-study, the the Yorkshire Lung Screening Trial (YLST),and the Yorkshire Kidney Screening Trial (YKST), all of which are sponsored by the University of Leeds and funded by the Yorkshire Cancer Research (award references: L403, L403B, L403C),in collaboration with the University of Manchester, the University of Leeds and Leeds Teaching Hospital Trust (LTHT).
More information about LEVANTIS-0093A can be found at ClinicalTrials.gov (NCT05295017).
The University of Leeds is one of the largest higher education institutions in the UK, with more than 38,000 students from more than150 different countries. We are renowned globally for the quality of our teaching and research.
We are a values-driven university, and we harness our expertise in research and education to help shape a better future for humanity, working through collaboration to tackle inequalities, achieve societal impact and drive change.
The University is a member of the Russell Group of research-intensive universities, and plays a significant role in the Turing, Rosalind Franklin and Royce Institutes.
Leeds Teaching Hospitals NHS Trust is one the largest and busiest acute hospital trusts in Europe. Every year the Trust provides healthcare and specialist services for people from the city of Leeds, Yorkshire and the Humber and beyond. The Trust plays an important role in the training and education of medical, nursing and dental students, and are a centre of world-class research and pioneering new treatments.
Leeds Teaching Hospitals has a budget of £1.4 billion and employs around 20,000 people. Care and clinical expertise is delivered from seven hospitals on five sites, and they are all joined by a vision to be the best for specialist and integrated care.
Staff at Leeds Teaching Hospitals helped to define the values and behaviours that all staff should work to, and this has become known as The Leeds Way. This forms the foundation of the Trust’s culture, ethos and how the hospitals work every day.
The Trust’s Building the Leeds Way programme includes the construction of a new state-of-the-art adults’ hospital and a new home for Leeds Children’s Hospital on the Leeds General Infirmary site. It also includes the development of a new pathology laboratory at St James’s Hospital and the use of old estate at Leeds General Infirmary to create a new Innovation District for Leeds bringing about direct and wider economic benefits of up to £11.2bn in net present value terms and more than 3,000 jobs.
Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality by enabling earlier detection and closer monitoring. The metabolism-based liquid biopsy platform in development measures a novel panel of biomarkers and utilizes machine learning algorithms to generate cancer-type specific GAG scores. Elypta is advancing a broad study program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma.
Karl Bergman, CEO, karl.bergman@elypta.com
Tel: +46 73 262 53 33.
